Date:- 27 June, 2016
Initially framed to cover a limited number of in-vitro-diagnostic (IVD) development projects conducted by HalioDx on behalf of QIAGEN, both companies have now agreed to extend this R&D service agreement for another four years to include additional cancer IVD development projects.
Partnering activities are conducted at HalioDx by a team of 60 highly qualified collaborators operating in the company facilities in Marseille, France, under the relevant quality system and a Design Control compliant process aligned with US and Europe regulatory requirements.
Stephane Debono, Executive Vice President Operations and Finances of HalioDx commented: “The extension of our partnership with QIAGEN exemplifies our customer-centric vision and the talent and commitment of our teams in delivering on-time complex IVD projects in a highly regulated and competitive context. It is indeed a very positive signal for potential other partners such as pharma companies.”